non-castration-resistant prostate cancer affects the further therapeutic effect of docetaxel when patients become castration resistant. Herein, our aim was to investigate the prognostic value of response duration of ADT in castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy.
INTRODUCTION AND OBJECTIVES: To evaluate whether metformin (Met) a widely-used, nontoxic oral antidiabetic drug with putative anticancer properties leads to improvements in prostate cancer (PC) outcomes in the CHAARTED trial.
METHODS: In the CHAARTED database where metformin use at baseline was recorded prospectively, we identified patients with metastatic PC who underwent either ADT alone or ADT and docetaxel (D) chemotherapy. Cox proportional hazards models were used to determine the effect of Metformin on outcomes.
RESULTS: A total of 788 patients (median age, 63 y) had complete data after randomization. Comparison of ADTþDþMet (n¼39) to ADTþD (n¼357) and ADTþMet (n¼29) to ADT alone (n¼363) revealed similar clinicopathologic characteristics. Cause of death was PC in 13(81%) of ADTþDþMet, 72(85%) ADTþD, 9(82%) ADTþMet and 105(84%) ADT alone groups. See table for PC outcomes and overall survival by metformin use. Cox regression analysis for overall survival stratified by stratification factors at randomization demonstrates Met use was associated with a trend for worse overall survival (HR 1.47 95%CI: [0.95, 2.26] , p¼0.08) with adjustment for treatment arm and prior local therapy. In contrast, ADTþD use (HR 0.62; 95%CI: [0.47,0.81]) and prior local therapy with surgery or radiation (HR 0.56; 95% CI: [0.38, 0.82]) were associated with improved survival.
CONCLUSIONS: In this study, baseline metformin use for patients with advanced metastatic PC did not improve PC outcomes. However, early ADT and docetaxol improved survival as did a history of local treatment of the primary tumor. 
INTRODUCTION AND OBJECTIVES:
Metformin is a commonly prescribed glucose-lowering therapy for patients with type 2 diabetes mellitus (T2DM). Basic research supports a synergistic antineoplastic effect of metformin for various cancers including prostate cancer (PC). We hypothesize that metformin plus androgen deprivation therapy (ADT) may be synergistic in men with advanced PC.
METHODS: Using national Veterans Affairs databases, we identified all men diagnosed with PC between 2000-2008 that were treated with ADT and had follow-up through October of 2015. We excluded patients that were treated with ADT for 6 months or were receiving ADT concurrently with localized radiation therapy. Three cohorts were identified including non-diabetics, diabetics on metformin, and diabetics not on metformin. Our primary outcome was overall survival (OS) and secondary outcomes included skeletal related events (SRE) and PC-specific survival.
RESULTS: The total cohort after exclusions consisted of 87,344 patients of which 53,893 (61%) were non-diabetics, 14,517 (17%) were diabetics on metformin and 18,934 (22%) were diabetics not on metformin. Mean age was 75 AE11y (non-diabetics), 71 AE12 (diabetics on metformin), and 75 AE10 (diabetics not on metformin), p<0.001. The median OS was 7.1, 9.1 and 7.4 y respectively (p<0.001). Multivariable Cox proportional hazards analysis assessing for predictors of OS showed improved survival in diabetics on metformin (HR 0.77, 95% CI 0.74-0.81; p<0.001) vs. diabetics not on metformin (HR 0.99, 95% CI 0.95-1.03; p¼0.5) with non-diabetics as referent group while controlling for age, co-morbidity, and Gleason score. Assessing for predictors of SRE revealed no association between metformin use (HR 0.99, 95% CI 0.92-1.07; p¼0.8) and SRE. Lastly, PC-specific survival was improved in diabetics on metformin (HR 0.72, 95% CI 0.67-0.78; p<0.001) and to a lesser extent diabetics not on metformin (HR 0.87, 95% CI 0.81-0.93; p<0.001) with non-diabetics as referent group.
CONCLUSIONS: Metformin use in Veterans with advanced PC receiving ADT is associated with improved OS and cancer-specific survival. Improved outcomes for PC patients receiving metformin should be evaluated in a prospective clinical trial. 
Source of

INTRODUCTION AND OBJECTIVES: Seminal vesicle invasion
(SVI) is a risk factor for poor oncologic outcome in patients with prostate cancer (PC). The total number of lymph nodes removed (lymph node yield [LNY]) during radical prostatectomy (RP) has been reported to have a diagnostic and therapeutic benefit in patients with clinically localized disease regardless of node positivity. This benefit in patients with SVI has not been previously assessed. METHODS: We identified 221 patients retrospectively from two medical centers who underwent RP without adjuvant treatment between 1990-2015 and had PC with SVI (i.e. pT3b). BCR was defined as a postoperative PSA >0.2 ng/mL, or use of salvage androgen deprivation therapy (ADT) or radiation in response to a clinical suspicion of progression. Multivariable cox proportional hazards models were used to determine if LNY was predictive of BCR. The Kaplan-Meier method was used to determine the 3-yr freedom from BCR. RESULTS: Median LNY was 8 (IQR: 4-13). With a median follow-up of 56.9 months, the estimated 3-year freedom from BCR for overall, N0, and N1 patients was 55.7%, 59.0% and 28.3% respectively. Results from multivariable analysis demonstrated that LNY was not significantly associated with risk of BCR for overall (HR¼1.01, p¼.734), for pN0 (HR¼1.00, p¼.825) or pN1 patients (HR¼1.02¼.744). PSA (HR¼1.02, p<.001), pathologic Gleason sum ¼ 9 (HR¼1.90, p¼.006), more recent RP (HR¼1.07, p¼.004), bladder neck invasion (HR¼1.98, p¼.056) and N1 disease (HR¼2.19, p¼.003) were associated with an increased risk of BCR. Increasing LNY increased the likelihood of detecting more positive lymph nodes (ß¼0.19, p¼.003) in pN1 patients.
CONCLUSIONS: SVI after RP is associated with a high risk of BCR. While greater LNY facilitate increased accuracy in staging, our study demonstrates that in the setting of SVI, pathologic Gleason score and PSA at diagnosis are the primary drivers of BCR. THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
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